MG

Murali Gadupudi

Director Director DIN 02619699
DIN 02619699 First appointment Dec 2006 Primary industry Pharma
Unlock full profile Investments Β· shareholding Β· contact details
Past companies 2 historical roles
Total affiliations 2 Since Dec 2006
Shareholding value β€’β€’β€’β€’ Premium profile

About Murali Gadupudi

Data last updated:

Murali Gadupudi was a Director at Stevia Pharmaceuticals Private Limited (2006–2010) and Director at Rozzor Pharmaceuticals Private Limited (from 2010). The companies operate in Pharma.

DIN 02619699
Primary Designation Director
Industry Pharma
First Appointment 26 Dec 2006
Oldest Company Age 16 yrs

Previous companies

CompanyDesignationAppointmentFoundedRevenueStatus
Director26 Dec 20062006₹1.46 Cr (FY 2025)Active
Director15 Apr 20102010Strike Off

Explore Director's current and past company associations Uncover their professional journey today!

Directorship timeline

Open interactive timeline →
Rozzor Pharmaceuticals Private Limited
Stevia Pharmaceuticals Private Limited
Premium access

Shareholding and investment profile for Murali Gadupudi

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Murali Gadupudi

Murali Gadupudi was first appointed on 26 Dec 2006 as Director at Stevia Pharmaceuticals Private Limited. The most recent appointment on record is 15 Apr 2010 at Rozzor Pharmaceuticals Private Limited.

Murali Gadupudi held 2 earlier board appointments: Stevia Pharmaceuticals Private Limited (Director, 26 Dec 2006 to 01 Dec 2010); Rozzor Pharmaceuticals Private Limited (Director, from 15 Apr 2010).

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available